{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 41,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/16",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve comparing binimetinib vs dacarbazine",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6e9a621-1027-4c45-9bef-3e2ccd18e5c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "list",
      "text": "Naporafenib (pan-RAFi): Completed US/EU EOP2 process; Compelling efficacy (mPFS ~5 months); FDA Fast Track; Potential to be first-to-market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bbe61e2-a7d9-4813-a881-b1d78c7012b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "Incidence: ~54,000 patients diagnosed with NRASm melanoma in the US and Europe annually",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d7633ac-351b-4441-8f35-c1de23d1291c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.02,
        "y": 0.35
      },
      "kind": "list",
      "text": "Standard-of-Care: NRAS mutation related to aggressive disease traits; No targeted therapy approved; Current treatment options post-IO are dismal",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2cac0d0-3a5f-4bd6-a8ba-59b5d62dfe2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.52,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "Adapted from Dummer et al. (Lancet Oncol 2017); Benchmarks most relevant for SC-2",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18fa0f3f-c419-48d7-8dbb-1358f65da829",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.95,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "SEACRAFT-2: Naporafenib + trametinib has the potential to be first-in-class targeted treatment for NRASm melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee13bf8-c133-4f2d-be24-722abb428a77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "05020427-0338-4395-a07a-aaa62c3a5abf",
      "evidence": "Standard-of-Care: NRAS mutation related to aggressive disease traits; No targeted therapy approved; Current treatment options post-IO are dismal",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
      "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
      "position": 1,
      "objective": "What are the potential benefits of investing in Erasca's pipeline?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    },
    {
      "to": 18,
      "from": 16,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "15811b97-f573-4124-b3e9-b52968ac14b4",
      "evidence": "The deck presents case studies and testimonials from patients and clinicians",
      "position": 2,
      "objective": "What do patients and clinicians need from cancer treatments?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}